Trump’s Drug-Pricing Push to Cut Access Outside US, Study Finds

The Trump administration’s push to bring US drug spending down is a powerful incentive for pharmaceutical companies to boost prices and reduce access elsewhere in the world, a study found.

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.